These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11155746)

  • 41. Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors.
    Garrido Abad P; Sinués Ojas B; Martínez Blázquez L; Conde Caturla P; Fernández Arjona M
    Actas Urol Esp; 2015 Dec; 39(10):635-40. PubMed ID: 26049734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does compression of the base of the penis improve the efficacy of intracavernosal injection of prostaglandin E1 for impotence? A randomized controlled study.
    el-Saleh JC; Keogh EJ; Chew KK; Earle CM; Lee JL; Wearmouth JW
    Int J Impot Res; 1995 Mar; 7(1):23-31. PubMed ID: 7670590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of sexual impotency by intra-cavernous injections of prostaglandin E1. Report of 180 patients].
    Amar E; Kobelinsky M; Khoury R; Sarkis P; Bouyer I; Dauphin A; Delmas V; Boccon-Gibod L
    Prog Urol; 1993 Dec; 3(6):971-8. PubMed ID: 8305940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A prostaglandin E1 dose-response study in man.
    von Heyden B; Donatucci CF; Marshall GA; Brock GB; Lue TF
    J Urol; 1993 Dec; 150(6):1825-8. PubMed ID: 8230515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prostaglandin treatment in neurological patients with erectile dysfunction].
    Conejero Sugrañes J; Muñoz Villellas A; Sarrias Lorenz F; Ramírez Garceran L
    Arch Esp Urol; 2002; 55(1):63-8. PubMed ID: 11957754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A positive pharmacological erection test does not rule out arteriogenic erectile dysfunction.
    Cormio L; Nisén H; Selvaggi FP; Ruutu M
    J Urol; 1996 Nov; 156(5):1628-30. PubMed ID: 8863555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of nocturnal penile erection test on response to daily sildenafil in patients with erectile dysfunction due to pelvic fracture urethral disruption: a single-center experience.
    Peng J; Zhang Z; Cui W; Yuan Y; Gao B; Song W; Xin Z
    Urology; 2014 Dec; 84(6):1389-94. PubMed ID: 25306478
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Intracavernous injections of prostaglandin E1 in the treatment of erection disorders].
    Beretta G; Zanollo A; Portalupi W
    Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):481-5. PubMed ID: 1838836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Real-time Rigiscan monitoring and color Doppler ultrasonography in the diagnosis of erectile dysfunction].
    Tang Y; Liu Z; Jiang X; Wen J; Chen H; He L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 34(1):81-4. PubMed ID: 19197134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of penile vascular effect induced by intracavernous injection of papaverine and prostaglandin E1.
    Hwang TI; Lue TF; Yang CR; Chang CL; Chang CH; Wu HC
    Taiwan Yi Xue Hui Za Zhi; 1989 Oct; 88(10):1038-41. PubMed ID: 2634727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topical prostaglandin-E1 for the treatment of erectile dysfunction.
    Kim ED; McVary KT
    J Urol; 1995 Jun; 153(6):1828-30. PubMed ID: 7752328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
    Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
    J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Office treatment: intracavernous injections of prostaglandin E1 (PG E1) and improvement of spontaneous erections.
    Beretta G; Marzotto M; Zanollo A; Re B
    Acta Eur Fertil; 1991; 22(4):221-3. PubMed ID: 1844326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy.
    Hafez ES; Hafez SD
    Arch Androl; 2005; 51(1):15-31. PubMed ID: 15764414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Initial experiences with prostaglandin E1 and PGE1 prepared injections].
    Mattarelli G; Leibundgut B
    Helv Chir Acta; 1991 Sep; 58(3):335-7. PubMed ID: 1769856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1].
    Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B
    Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The use of PGE1 in the treatment of erectile deficiency].
    Arena F; Peracchia G; Di Stefano C; Cortellini P
    Acta Biomed Ateneo Parmense; 1996; 67(1-2):49-53. PubMed ID: 10021734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Possible hemodynamic pathways of intraurethral prostaglandin-E1 (MUSE).
    Bschleipfer T; Cimniak HU; Beckert R; Hauck EW; Weidner W; Sparwasser C
    Int J Impot Res; 2004 Aug; 16(4):365-8. PubMed ID: 14961055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.